i do miss in Norgine`s new release that Lymphoseek is available in Italy already since 20th september 2017. so what happened to LS in Italy (and other already launched regions?). is Norgine a premier-choice distributor?

https://www.norgine.com/press_release/norgine-launches-lymphoseekâ?¼-99mtc-tilmanocept-italy/


NORGINE LAUNCHES LYMPHOSEEK®▼ (99mTc-tilmanocept) IN ITALY

Share article:

Back to media releases
Next media release
20 September 2017

CORPORATE MEDIA RELEASE

NORGINE LAUNCHES LYMPHOSEEK®▼ (99mTc-tilmanocept) IN ITALY



AMSTERDAM. The Netherlands. 14:00 CET. Norgine B.V. today announced the launch of LYMPHOSEEK® (technetium Tc 99m tilmanocept) in Italy. LYMPHOSEEK® is a radiopharmaceutical used for diagnostic purposes by nuclear medicine specialists and surgeons. It is specifically designed for a procedure called sentinel lymph node biopsy (SLNB) and represents a significant alternative to the current method of identifying sentinel lymph nodes in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.

LYMPHOSEEK® has been specifically designed to target, bind to and be retained in sentinel lymph nodes, the first lymph node (or group of nodes) to which cancer cells are most likely to spread from a primary tumour.[1],[2],[3] LYMPHOSEEK® has a false negative rate of 2.6% in T1-T4cN0 oral squamous cell carcinoma (OSCC).[1] It detected sentinel lymph nodes in 98% of patients with Tis, Tx or T1-T4cN0 breast cancer and T1-T4cN0 melanoma.[1],[4]




Lymphoseek available in Germany (finally)

i do not remind to read any launching-announcement by Norgine for launch in Germany, yet they now write:

---

LYMPHOSEEK®– a novel radiopharmaceutical used in sentinel lymph node biopsy (SLNB), in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity. LYMPHOSEEK® was launched in additional markets across Europe. It is available in Denmark, the Netherlands, the UK, GERMANY and Spain.